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Summary
Transcription factor Nrf2 and its repressor Keap1 regulate a
network of cytoprotective genes involving more than 1% of the
genome, their best known targets being drug-metabolizing and
antioxidant genes. Here we demonstrate a novel role for this
pathway in directly regulating mitochondrial bioenergetics in
murine neurons and embryonic fibroblasts. Loss of Nrf2 leads
to mitochondrial depolarisation, decreased ATP levels and
impaired respiration, whereas genetic activation of Nrf2
increases the mitochondrial membrane potential and ATP
levels, the rate of respiration and the efficiency of oxidative
phosphorylation. We further show that Nrf2-deficient cells
have increased production of ATP in glycolysis, which is then
used by the F1Fo-ATPase for maintenance of the mitochondrial
membrane potential. While the levels and in vitro activities of
the respiratory complexes are unaffected by Nrf2 deletion,
their activities in isolated mitochondria and intact live cells are
substantially impaired. In addition, the rate of regeneration of
NADH after inhibition of respiration is much slower in Nrf2-
knockout cells than in their wild-type counterparts. Taken
together, these results show that Nrf2 directly regulates
cellular energy metabolism through modulating the
availability of substrates for mitochondrial respiration. Our
findings highlight the importance of efficient energy
metabolism in Nrf2-mediated cytoprotection.
 2013. Published by TheCompany of Biologists Ltd. This is an
Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/
licenses/by/3.0), which permits unrestricted use, distribution
and reproduction in any medium provided that the original
work is properly attributed.
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Introduction
To adapt and survive, eukaryotic organisms have evolved
an elaborate network of cytoprotective proteins (e.g.
NAD(P)H:quinone oxidoreductase 1, glutathione transferases,
c-glutamylcysteine ligase, heme oxygenase 1). Functionally, they
are extraordinarily versatile and, by mechanisms which include
direct antioxidant activity, obligatory 2-electron reduction
reactions, conjugation with endogenous ligands, recognition,
repair and removal of damaged proteins, efficiently detoxify
numerous endogenous and exogenous damaging agents, and
facilitate their elimination (Baird and Dinkova-Kostova, 2011;
Kensler et al., 2007; Nguyen et al., 2009; Talalay, 2000). These
cytoprotective proteins share common transcriptional regulation,
through the Keap1-Nrf2 pathway. Under basal conditions Kelch-
like ECH-associated protein 1 (Keap1) binds and targets
transcription factor Nuclear factor E2-related factor 2 (Nrf2)
for ubiquitination and proteasomal degradation via association
with Cullin 3-based E3 ubiquitin ligase. Inducers of this pathway
react and chemically modify specific cysteine residues of Keap1,
which consequently loses its ability to target Nrf2 for
degradation. This leads to increased stabilization of Nrf2, its
nuclear translocation, and ultimately to coordinate expression of
cytoprotective genes. Deletion of Nrf2 renders cells and animals
much more sensitive to the damaging effects of electrophiles,
oxidants, and inflammatory agents in comparison to their wild-
type counterparts; conversely, pharmacological or genetic
activation of Nrf2 has protective effects in numerous models of
chronic disease (Hayes et al., 2010). Thus, the ability to
upregulate Nrf2-dependent genes is crucial for adaptation and
survival.
Because of its highly effective and comprehensive
cytoprotective role against the consequences of oxidative stress
and inflammation, the underlying causes for essentially all
chronic degenerative diseases, Nrf2 is now widely recognized as
a drug target (Crunkhorn, 2012). Indeed, several activators of
Nrf2 have been or currently are in clinical trials. Bardoxolone
methyl treatment has been used in advanced chronic kidney
disease associated with type 2 diabetes (Pergola et al., 2011a;
Pergola et al., 2011b), while dimethyl fumarate has been tested in
patients with relapsing-remitting multiple sclerosis (Gold et al.,
2012). In human subjects exposed to aflatoxins and air-borne
toxins, standardized preparations of broccoli sprouts as sources of
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the Nrf2 activator sulforaphane or its precursor, glucoraphanin,
have shown enhanced detoxification of these environmental
toxins, which may in turn lower the health risks associated with
such exposures (Kensler et al., 2013).
Emerging experimental evidence suggests that Nrf2 not only
activates antioxidant, drug metabolizing, and anti-inflammatory
genes in response to stress, but also influences primary
metabolism and bioenergetics. Thus, the expression of malic
enzyme and three of the enzymes of the pentose phosphate
pathway (namely, glucose-6-phosphate dehydrogenase,
transaldolase, and transketolase), is severely decreased in the
absence of Nrf2 (Lee et al., 2003a; Lee et al., 2003b; Mitsuishi et
al., 2012; Thimmulappa et al., 2002; Wu et al., 2011). Together,
the catalytic power of these enzymes provides precursors for the
biosynthesis of basic metabolites such as reducing equivalents
(e.g. NADPH) for the maintenance of glutathione in its reduced
state and for the fatty acid biosynthesis, ribose-5-phosphate for
the biosynthesis of nucleotides, and erythrose-4-phosphate for the
biosynthesis of aromatic amino acids. Most recently, it was
shown that Nrf2 redirects glucose and glutamine into anabolic
pathways, especially under conditions of sustained activation of
the PI3K-AKT signaling pathway (Mitsuishi et al., 2012). This
function of Nrf2, together with the fact that upregulation of its
target genes lowers oxidative stress and inflammation, can not
only protect against the onset of disease, including cancer, but
under certain conditions, such as those occurring during
constitutive K-Ras and B-Raf signaling, may also favor the
growth of established tumors (DeNicola et al., 2011).
Curiously, oxygen consumption and ATP production are
decreased following siRNA-mediated Nrf2 knockdown in colon
cancer cells (Kim et al., 2011), but the underlying reasons for this
observation are not known. Because Nrf2 is a transcription factor
implicated in the expression of more than 500 genes (Malhotra et
al., 2010), one possibility is that it directly affects the expression
of genes coding for protein subunits that comprise the
mitochondrial respiratory chain. Alternatively, Nrf2 may
control indirectly the function of these proteins by regulating
the availability of their substrates. To test these hypotheses, we
used a panel of live cell imaging techniques and biochemical
enzymatic assays to assess mitochondrial function in primary
neuronal cultures, mouse embryonic fibroblasts (MEFs) as well
as isolated mitochondria from WT, Nrf2 knockout (KO) and
Keap1 KO or knockdown (KD) mice. Strikingly, we found that,
in the absence of Nrf2, the mitochondrial function is impaired,
whereas under condition of constitutive activation of Nrf2, the
mitochondrial function is enhanced. Importantly, some of the
phenotypic changes associated with Nrf2 deficiency can be
rescued by the addition of substrates for the mitochondrial
respiration, suggesting a previously unrecognized role for the
Keap1-Nrf2 pathway in the control of substrate availability.
These findings highlight both the novel role for the pathway in
directly modulating mitochondrial metabolism as well as the
importance of mitochondrial metabolism in Nrf2-mediated
cytoprotection.
Results
Nrf2 affects the mitochondrial membrane potential
To establish the role of Nrf2 in cellular energy metabolism, we
characterized the effects of this transcription factor on the
mitochondrial membrane potential, respiration, ATP production,
and redox homeostasis, as well as on the activity of the
mitochondrial complexes using mitochondria, cells, and tissues
isolated from wild-type (WT), Nrf2-knockout (Nrf2-KO), Keap1-
knockout (Keap1-KO), or Keap1-knockdown (Keap1-KD) mice.
Nrf2-KO mice have low and uninducible levels of Nrf2-target
proteins (Itoh et al., 1997). Conversely, Keap1-KO mice have
constitutively high levels of Nrf2 and its downstream target
proteins; however, they die postnatally due to esophageal
hyperkeratosis (Wakabayashi et al., 2003). In contrast, Keap1-
KD mice are viable: they carry a floxed allele of the keap1 gene,
which reduces its expression and consequently increases the
levels of Nrf2, and thus represent a genetic model for constitutive
Nrf2 activation (Taguchi et al., 2010).
Using live cell imaging, we began by measuring the
mitochondrial membrane potential (Dym), a universal indicator
of mitochondrial health and the metabolic state of the cell.
Compared to WT, Nrf2-KO mouse embryonic fibroblasts (MEFs)
have significantly reduced basal Dym (79.265.1% of control,
n.400; P,0.05) (assessed by the fluorescent probe
tetramethylrhodamine methylester, TMRM); this difference in
Dym was further accentuated (to 49.7610.5% of control, n.400;
P,0.001) in the absence of glucose (Fig. 1A). Although not
statistically significant, Dym was slightly higher in Keap1-KO
compared to WT cells (Fig. 1A, n.400). Further investigations
using primary cortical neurons confirmed the findings in MEFs:
Dym in Nrf2-KO was 79.864.1% of control cells (n558;
P,0.001) and 117.967.3% in Keap1-KD cells (n547; P,0.05;
Fig. 1B). Importantly, there was no difference in the relative
mitochondrial mass in neurons from the different genotypes
(n553; Fig. 1C).
In healthy cells the mitochondrial respiratory chain maintains
the Dym. In the event of damage or inhibition of respiration, cells
may maintain Dym by ATP hydrolysis through the F1Fo-ATPase,
thus restoring the proton gradient across the membrane.
Application of oligomycin, an inhibitor of the F1Fo-ATPase, to
WT midbrain neurons (n544) induced no response or a slight
hyperpolarisation as proton entry through the F1Fo-ATPase was
inhibited, as was the case in Keap1-deficient cells (n553)
(Fig. 1D). In contrast, oligomycin (2 mg/ml) caused marked
mitochondrial depolarisation in Nrf2-KO neurons (41.662.7%
decrease in TMRM signal, n562; Fig. 1D), suggesting that the
Dym is largely maintained by the hydrolysis of ATP by the F1Fo-
ATPase, rather than by respiration.
The differences in basal Dym among the genotypes suggest
that Nrf2 deficiency could change the activity of the
mitochondrial electron transport chain. To test this possibility,
we applied to primary cortical neurons substrates for the TCA
cycle (malate/pyruvate) which in turn increase the production of
the complex I substrate, NADH. We then also added methyl
succinate, a substrate for complex II. As expected, in WT cells
the sequential addition of malate, pyruvate, and methyl succinate
caused a stepwise increase in TMRM fluorescence (Fig. 1E,
n558). Interestingly, the magnitude of the effect of pyruvate and
methyl succinate was much greater in Keap1-KD neurons (by
2160.2% for malate, by 34.562.3% for pyruvate, and by
68.465.8% for methyl succinate) (Fig. 1G, n544). Most
strikingly, the shape of the response was different. The TMRM
fluorescence rapidly increased in response to each substrate;
however, it also quickly decreased, suggesting an unusually fast
substrate consumption. Notably, these results are consistent with
the much lower (by 50–70%) levels of malate, pyruvate and
succinate that were observed after a 1-h pulse of [U-13C6] glucose
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in Keap1-KO compared to WT MEFs (Mitsuishi et al., 2012). In
sharp contrast to WT and Keap1-KD cells, application of both
malate and methyl succinate induced a slight depolarisation in
Nrf2-KO neurons, and only pyruvate was able to hyperpolarise
the mitochondria in these cells (Fig. 1F, n561).
Nrf2 regulates respiration
Mitochondrial respiration is dependent on the Dym. We therefore
evaluated the effect of Nrf2 on oxygen consumption in intact
cells and isolated mitochondria. Compared to WT, oxygen
consumption in Nrf2-KO and Keap1-KO MEFs was reduced by
,50% and,35%, respectively at the basal state (Fig. 2A, basal).
Inhibition of the F1Fo-ATPase by oligomycin decreased
respiration by 40% in WT cells, but this effect was attenuated
in both Nrf2-KO and Keap1-KO cells, with Nrf2-KO cells
showing almost complete insensitivity to oligomycin (Fig. 2A,
oligomycin). Upon addition of the uncoupler FCCP, the oxygen
consumption of WT cells nearly doubled, (Fig. 2A, FCCP). The
effect of FCCP was similar in Nrf2-KO, but was diminished in
Keap1-KO cells (Fig. 2A).
To investigate the differences in respiration in detail, we
isolated mitochondria from brain and liver of WT, Nrf2-KO and
Keap1-KD animals. The rate of oxygen consumption in state 4
respiration was dependent on substrates and it was observed in
mitochondria of different tissue origin. Thus, malate induced a
higher rate of oxygen consumption in Keap1-KD mitochondria
compared to WT (2.3-fold increase in rate compared to WT;
n53, P,0.0001) and had a significantly smaller effect on Nrf2-
KO mitochondria (2.1-fold decrease in rate compared to WT;
n53, P,0.0001; Fig. 2B). Application of Complex II substrate
(succinate in the presence of rotenone; Fig. 2C) also activated
oxygen consumption more strongly in Keap1-KD (2.7-fold
increase in rate compared to WT; n53, P,0.0001) compared
to WT mitochondria; its effect was opposite in Nrf2-KO (2.9-fold
decrease in rate compared to WT; n53, P,0.0001). Stimulation
of mitochondria with glutamate or pyruvate had similar effects on
WT, Keap1-KD and Nrf2-KO mitochondria (not shown). The
respiratory control ratio (RCR), the ratio of state 3 (ADP-
stimulated) to state 4 respiration (no ADP present), is an
indication of the degree of coupling of the mitochondrial
respiratory chain activity to oxidative phosphorylation (Chance
and Williams, 1955). The RCR was decreased in Nrf2-KO
mitochondria, while Keap1-KD showed almost no difference
compared to WT, indicating that the higher rate of respiration in
Fig. 1. Nrf2 affects the mitochondrial membrane potential. (A) Mitochondrial membrane potential in WT, Nrf2-KO and Keap1-KO MEFs in the presence or
absence of glucose determined by TMRM fluorescence. (B) Mitochondrial membrane potential in primary cortical neurons from WT, Nrf2-KO and Keap1-KD mice.
(C) Relative mitochondrial mass in Nrf2-KO and Keap1-KD cortical neurons compared to WT cells, measured as the co-localisation of TMRM with the cytosolic
calcium dye fluo-4. (D) TMRM fluorescence in WT, Nrf2-KO and Keap1-KD cortical neurons after addition of oligomycin (2 mg/ml) and FCCP (0.5 mM).
(E–G) TMRM fluorescence after sequential addition of malate, pyruvate and methyl succinate (5 mM each) in WT (E), Nrf2-KO (F) and Keap1-KD (G) cortical
neurons. FCCP was added in the end to fully depolarise the mitochondria. Data presented as mean percentage compared to WT 6 SEM *P,0.05 **P,0.001.
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Keap1-KD mitochondria is not due to uncoupling of oxidative
phosphorylation (Fig. 2D). The efficiency of oxidative
phosphorylation in mitochondria can be estimated as a ratio of
ADP to oxygen consumed for ATP synthesis. Nrf2 deficiency
significantly decreased oxidative phosphorylation efficiency in
brain and liver mitochondria, which could be due to inhibited
respiration and mild uncoupling. Conversely, Keap1-KD
mitochondria had a significantly higher ADP/O ratio suggesting
that oxidative phosphorylation in these mitochondria is more
efficient than in WT (Fig. 2E). Importantly, the differences in
respiration among the genotypes are not due to alterations in the
levels of the enzymes in the respiratory chain as the activities of
the mitochondrial Complex I, II and IV as well as the F1Fo-
ATPase in brain tissue isolated from animals of the three
genotypes, are very similar (Table 1; Fig. 2F).
Nrf2 affects the production of ATP
The reduced respiration and its insensitivity to oligomycin in
Nrf2-KO cells indicate that oxidative phosphorylation could be
impaired in the absence of Nrf2. We therefore compared the ATP
levels in neurons of the different genotypes (Fig. 3A), and
investigated the impact of oxidative phosphorylation (estimated
by inhibition with oligomycin) or glycolysis (estimated by
inhibition with iodoacetic acid – IAA). Compared to WT, the
basal level of ATP in Keap1-KD cells was significantly higher
(by 14.660.9%, n536; P,0.05), whereas it was lower (by
32.962.3%, n541; P,0.001) in Nrf2-KO cells (Fig. 3B). More
importantly, the use of inhibitors revealed that the mechanism of
ATP production differs among the genotypes. As expected, in
WT neurons, oligomycin caused a complete drop in ATP and
IAA had no further effect (Fig. 3C). Remarkably, in Nrf2-KO
Fig. 2. Nrf2 affects mitochondrial
respiration. (A) Oxygen consumption in WT,
Nrf2-KO and Keap1-KO MEF cells under
basal conditions or in the presence of
oligomycin (2 mg/ml) or FCCP (1 mM). State 4
respiration in isolated brain mitochondria from
WT, Nrf2-KO and Keap1-KD mice in the
presence of 5 mM malate (B) or 5 mM
succinate and rotenone (5 mM) (C).
(D) Respiratory control ratio, state 3
respiration (ADP stimulated) to state 4
respiration (no ADP present), in isolated
mitochondria from brain, heart and liver of
WT, Nrf2-KO and Keap1-KD mice. (E) Ratio
of ADP to oxygen in isolated mitochondria
from brain and liver of WT, Nrf2-KO and
Keap1-KD mice. Data presented as mean 6
SEM *P,0.05 **P,0.001. (F) Coommassie
stain of isolated mitochondria, identifying
mitochondrial respiratory chain complexes I,
II, III, IV and V (F1Fo-ATPase). (Fi) F1Fo-
ATPase activity, as seen by a grey precipitate
at the level of Complex V.
Table 1. Activities of respiratory chain enzymes in brain tissue isolated from WT, Nrf2 KO, and Keap1 KD 8-week-old male
mice (n54). All activities except complex IV (k/min/mg) are expressed as nmol/min/mg. Values are means 6 SEM.
Enzyme WT Nrf2 KO Keap1 KD
Complex I (NADH:ubiquinone reductase) 94.1564.4 89.4462.6 86.82567.3
Complex II (Succinate:ubiquinone reductase) 44.3563.7 48.2663.1 39.668.1
Complex IV (cytochrome c oxidase) 9.87560.5 10.4260.63 10.42561.4
Citrate synthase (mitochondrial marker enzyme) 405.0565.9 399.08613.3 395.7618.6
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cells, oligomycin increased the ATP levels (Fig. 3D), which
could be attributed to inhibition of ATP hydrolysis by the
mitochondrial ATPase (F1Fo-ATPase operating in reverse). Such
reversal in F1Fo-ATPase activity towards ATP hydrolysis rather
than synthesis could represent an attempt to pump protons across
the inner membrane in order to maintain the Dym, which
correlates with the depolarisation seen in TMRM fluorescence
after oligomycin (Fig. 1D). In contrast to the apparent lack of
inhibition of ATP synthesis by oligomycin, addition of IAA to
Nrf2-KO cells produced a fast and complete drop in ATP, further
pointing towards reliance on glycolysis for ATP production in
Nrf2-deficient cells, in full agreement with the dependence of
Dym on the presence of glucose in the medium. Such a fast
decrease in ATP level in repose to inhibitors of ATP production
suggests fast energy consumption in these cells. In Keap1-KD
cells, addition of oligomycin resulted in,80% drop in ATP, with
IAA producing a further ,20% decrease (Fig. 3E). These results
suggest that either Nrf2 deficiency or its constitutive activation
reduce the contribution of oxidative phosphorylation towards the
synthesis of ATP, and that this effect is especially profound under
conditions of Nrf2 deficiency, and are consistent with the
increased levels of glycolytic intermediates (G6P, F6P, DHAP,
pyruvate, and lactate) that were observed after NRF2 knockdown
(Mitsuishi et al., 2012).
Nrf2 affects the mitochondrial redox homeostasis
The role of the Keap1-Nrf2 pathway in maintaining the cellular
redox homeostasis by controlling the expression of genes
encoding enzymes involved in the synthesis, utilization and
regeneration of glutathione, thioredoxin and NADPH is well
recognized (Greco et al., 2011; Kirby et al., 2005; Lee et al.,
2003a; Thimmulappa et al., 2002). To test the possible
involvement of Nrf2 in the maintenance of the mitochondrial
redox homeostasis, we determined the levels of NADH and FAD
by their autofluorescence. Application of the mitochondrial
uncoupler FCCP to cells maximises respiration and completely
oxidizes the mitochondrial pool of NADH, manifesting as a
decrease in fluorescence (min) (Fig. 4A). Conversely, the
complex IV inhibitor NaCN suppresses respiration preventing
NADH oxidation and allowing the NADH pool to regenerate
fully (max). The redox index is expressed as a percentage of
basal NADH autofluorescence compared to max and min (D)
(Gandhi et al., 2009). Compared to WT (61.564.6%, n578), the
NADH redox index was significantly lower in Nrf2-KO MEFs
(36.462.7%, n559, P,0.001; Fig. 4B,D), whereas it was
unaffected in Keap1-KO cells (54.664.1%, n584; Fig. 4C,D).
Remarkably, the rate of regeneration of the pool of NADH after
NaCN addition was much slower in Nrf2-KO than the
corresponding rate in WT or Keap1-KO cells (Fig. 4F). In full
agreement, compared to WT (n578), the total mitochondrial
NADH pool was significantly increased in Keap1-KO
(121.466.7%; n584, P,0.05), and dramatically decreased in
Nrf2-KO cells (51.364.7%; n559, P,0.0001; Fig. 4E).
The FAD redox index was next assessed; in this case addition
of FCCP leads to an increase in fluorescence, whereas NaCN
results in a decrease (Fig. 5A). Interestingly, the FAD redox
index was higher in both Nrf2-KO (92.667.2%, n591, P,0.001;
Fig. 5B,D) and Keap1-KD (81.266.2%, n581, P,0.001;
Fig. 5C,D) neurons compared to WT (47.964.1%, n554;
Fig. 5A,D). Similar to the NADH data, the rate of regeneration
of FADH2 was slower in Nrf2-KO cells compared to their WT
and Keap1-KD counterparts (Fig. 5E). Notably, addition of
Fig. 3. Nrf2 modulates ATP production. (A) Cytosolic ATP in primary cortical WT, Nrf2-KO and Keap1-KD neurons transfected with AT 1.03, visualised as a
merge of fluorescence images at 527 nm (red) and 475 nm (green). Scale bars: 20 mm. (B) Quantification of basal levels of cytosolic ATP in primary cortical WT,
Nrf2-KO and Keap1-KD neurons. Data presented as mean 6 SEM *P,0.05 **P,0.001. (C–E) ATP levels as fluorescence as the ratio 527/475 nm in WT (C),
Nrf2-KO (D) and Keap1-KD (E) neurons after inhibition of oxidative phosphorylation by oligomycin (2 mg/ml) and glycolysis by iodoacetic acid (IAA – 20 mM).
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methyl succinate to Nrf2-KO neurons was unable to restore the
FAD levels to control values (Fig. 5F,G), whereas in Keap1-KD
cells, FAD, upon addition of methyl succinate, fell even below
WT values (Fig. 5F,H). This result is consistent with the altered
ability of the mutant cells to utilize methyl succinate to maintain
Dym, which is diminished under conditions of Nrf2 deficiency
(Fig. 1F), and dramatically accelerated under conditions of
constitutive Nrf2 activation (Fig. 1G).
As the mitochondrial function is central to the overall redox
homeostasis of the cell, we next determined the levels of
superoxide by using the fluorescent probe dihydroethidium in
WT, Nrf2-KO and Keap1-KO cells. Consistent with the impaired
mitochondrial function in the absence of Nrf2 that was
demonstrated by all of the experiments described above, we
found that Nrf2-KO have dramatically increased (3–4-fold) levels
of superoxide compared to WT cells (Fig. 6A). The overall levels
of reactive oxygen species (ROS), as determined by the
fluorescence of oxidized 29,79-dichlorodihydrofluorescein
diacetate, were also higher in Nrf2-deficient cells (Fig. 6B),
whereas the levels of reduced glutathione (GSH) were much
lower (Fig. 6C). Compared to WT, the activities of three well
known Nrf2-dependent enzymes, NAD(P)H: quinone acceptor
oxidoreductase 1 (NQO1), glutathione transferases (GSTs), and
malic enzyme, in liver and cortex were lower in Nrf2-KO and
higher in Keap1-KD mice, confirming the absence and the
constitutive activation, respectively of Nrf2 in the transgenic
animals (Fig. 7).
Discussion
The prevailing view of the Keap1-Nrf2 pathway, for which there
exists a wealth of experimental evidence, is that it lies at the heart
of cellular defense mechanisms and plays a crucial role in
adaptation and survival under conditions of stress. It has been
implicated as a potential chemoprotection and therapeutical
target in a range of diseases, from neurodegenerative disease,
chronic kidney disease and diabetes to cancer, and several Nrf2
activators have been or currently are in clinical trials (Calkins et
al., 2009; Hayes et al., 2010; Liby and Sporn, 2012; Zheng et al.,
2011). Nrf2 is known to act by orchestrating an elaborate genetic
program that enhances intrinsic cytoprotective functions,
including drug metabolizing, antioxidant, and anti-inflammatory
networks. The experiments reported here add another mechanism
of cytoprotection to the repertoire of functions of the Keap1-Nrf2
pathway, and demonstrate its profound influence on another line
of defense, namely the cell energy metabolism through regulation
of the availability of substrates for mitochondrial bioenergetics.
The similar activities of the mitochondrial complexes I, II and
IV (Table 1) among the genotypes strongly suggest that the
observed defects in respiration and the altered Dym in the mutant
cells are not due to differences in expression of the genes
encoding proteins which form these complexes. Instead, these
defects are most likely due to altered availability of substrates for
complex I (NADH) and II (FADH2). Indeed, in Nrf2-KO cells,
the mitochondrial pool of NADH is almost 2-fold lower
compared to control cells (Fig. 4E). This could be due to less
efficient production of NADH in the TCA cycle as evidenced by
the slower rate of regeneration of NADH in response to inhibition
of respiration (Fig. 4B,F). This conclusion is further supported by
the results from the experiments with substrates for the TCA
cycle (glutamate, pyruvate, and malate) which had much smaller
effects on the mitochondrial membrane potential and respiration
under condition of Nrf2-deficiency. In addition to complex I,
Fig. 4. Altered NADH homeostasis in Nrf2-deficient cells. NADH levels were measured using NADH autofluorescence in MEF cells. The redox index was
calculated as the basal level relative to maximal respiration after FCCP (1 mM) (0%) and inhibited respiration after NaCN (1 mM) (100%). The NADH pool was
expressed as absolute values between maximal and minimal respiration in WT (A), Nrf2-KO (B) and Keap1-KO (C) cells. (D) NADH redox state in WT,
Nrf2-KO and Keap1-KO. Data presented as mean 6 SEM *P,0.001. (E) Mitochondrial NADH pool in WT, Nrf2-KO and Keap1-KO. Data presented as
mean 6 SEM *P,0.05 **P,0.0001. (F) The recovery time of the NADH pool after NaCN in WT, Nrf2-KO and Keap1-KO MEFs.
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Nrf2 deficiency also affects complex II-dependent respiration by
limiting the generation of FADH2 in the flavoprotein of
mitochondrial complex II. Importantly, Nrf2 deficiency leads to
activation of glycolysis to compensate for the decreased ATP
production due to impairment in oxidative phosphorylation, and
also because of the increased ATP demands as a consequence of
the use of this energy molecule by the F1Fo-ATPase for the
maintenance of Dym.
The influence on mitochondrial metabolism could partially
explain the usefulness of Nrf2 activation in such a wide range of
pathological conditions. ATP deficiency has been implicated in
several diseases for which Nrf2 activation has been shown to be
Fig. 5. Altered FAD homeostasis in Nrf2-deficient cells. FAD levels were measured using FAD autofluorescence in primary cortical neurons. The redox index
was calculated as the basal level relative to maximal respiration after FCCP (100%) and inhibited respiration after NaCN (0%) in WT (A), Nrf2-KO (B) and
Keap1-KD (C) neurons. (D) FAD redox state in WT, Nrf2-KO and Keap1-KD. Data presented as mean 6 SEM *P,0.001. (E) The recovery time of the FAD pool
after NaCN in WT, Nrf2-KO and Keap1-KD cells. (F–H) FAD autofluorescence in WT (F), Nrf2-KO (G) and Keap1-KD (H) cortical neurons after additions of
5 mM methyl succinate, FCCP and NaCN.
Fig. 6. Increased oxidative stress in Nrf2-deficient cells. Levels of superoxide, as measured by dihydroethidium (DHE) (A), reactive oxygen species (ROS), as
measured by 29,79-dichlorodihydrofluorescein diacetate (B), and reduced glutathione (GSH) (C) in WT, Nrf2-KO and Keap1-KO MEF cells.
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protective, such as neurodegeneration and diabetes (Burchell et
al., 2010; Schuit et al., 2001; Yao et al., 2011), while the switch
from oxidative phosphorylation to glycolysis in the presence of
oxygen is a hallmark of cancer (Warburg, 1956). The decrease of
energy levels in the cells makes them more susceptible to
undergo bioenergetics collapse in response to high energy
demand activities which eventually may lead to cell death as
seen in ischemia and glutamate-induced excitotoxicity (Abramov
and Duchen, 2010; Wang et al., 1994). It would also severely
impact the functions of the cell as most cellular activities require
ATP, from biosynthetic processes to channel activation to kinase
activity to signal transduction and cell division (for a review, see
Duchen, 2004). Our work highlights the importance of efficient
energy metabolism in cytoprotection and implicates Nrf2 as a key
regulator of this process.
The most efficient way to produce ATP in the cell is through
oxidative phosphorylation. However, increased oxidative
phosphorylation comes with the price of increased oxidative
stress, as the mitochondria are the major source of ROS in the
cell. In the case of Nrf2 activation, this is compensated for by the
increase in antioxidant capacity through enhanced expression of
genes encoding enzymes such as NQO1, GST, heme oxygenase
1, thioredoxin reductase, and elevated levels of reduced
glutathione and thioredoxin (Baird and Dinkova-Kostova, 2011;
Hayes et al., 2010). Previous findings have suggested a role for
the Keap1-Nrf2 pathway in mitochondrial function; however,
until now the underlying mechanisms have been unclear. We now
show that one way by which Nrf2 influences mitochondrial
function is through the modulation of the utilization of substrates
for mitochondrial respiration. Interestingly, the same substrates
(NADH and FADH2) are important for the function of
antioxidant enzymes, whose gene expression is also controlled
by the Keap1-Nrf2 pathway (Baird and Dinkova-Kostova, 2011;
Hayes et al., 2010). This enforces the reciprocal relationship
between oxidative phosphorylation and the redox state of the cell,
and the key role of the Keap1-Nrf2 pathway in regulating this
balance. The implications of our findings are far-reaching in
terms of understanding the multitude of functions of the Keap1-
Nrf2 pathway in health and disease.
Materials and Methods
Animals
Animal breeding and maintenance were in accordance with the regulations
described in the UK Animals (Scientific Procedures) Act 1986. WT, Nrf2 KO, and
Keap1 KD C57BL/6 mice were from breeding colonies established at the Medical
School Resource Unit, University of Dundee. The animals were kept on a 12-h
light/12-h dark cycle, 35% humidity, and were given free access to water and food
(pelleted RM1 diet from SDS Ltd., Witham, Essex, UK).
Cell culture and transfection
Mixed cultures of cortical or midbrain neurons and glial cells were prepared as
described (Vaarmann et al., 2010), from mouse pups 1–3 days postpartum.
Neurons were easily distinguishable from glia: they appeared phase bright, had
smooth rounded somata and distinct processes, and lay just above the focal plane
of the glial layer. Cells were used at 14–21 DIV. For measurements of ATP, the
Fig. 7. Nrf2-dependent enzyme activities in wild-type,
Nrf2- and Keap1-deficient tissues. Hepatic
(A,C,E) and cortical (B,D,F) enzyme activities of NQO1
(A,B), GST (C,D), and malic enzyme (E,F). All
experiments were performed on tissues isolated from
8-week-old WT, Nrf2-KO, Keap1-KD male mice.
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cells were transfected for 24 h with the ATP sensing probe AT1.03 (Imamura et
al., 2009) using Lipofectamine 2000 according to the manufacturer’s instructions.
Mouse embryonic fibroblasts (MEFs) derived from day 13.5 embryos of wild-
type, Nrf2-knockout, or Keap1-knockout C57BL/6 mice were maintained in
culture dishes coated for 30 min with 0.1% (w/v) gelatin. Cells were grown in
Iscoves Modified Dulbecco’s Medium (with L-glutamine), supplemented with
10% (v/v) heat-inactivated fetal bovine serum, 16 insulin–transferrin–selenium,
and 10 ng/ml epidermal growth factor, all from Gibco–Invitrogen, Paisley, UK.
Cultures were maintained at 37 C˚ in a humidified atmosphere of 5% CO2 and 95%
air.
Fluorescence measurements
For measurements of Dym, cells were loaded with 25 nM tetramethylrhodamine
methylester (TMRM) for 30 min at room temperature in HBSS (156 mM NaCl,
3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose, and
10 mM HEPES, pH adjusted to 7.35), and the dye was present during the
experiment. TMRM is used in the redistribution mode and therefore a reduction in
TMRM fluorescence represents Dym depolarization. In order to avoid any effects
of multi drug resistant pump (MDR) on the level of the indicators in the cells in
some experiments we used 10 mM Cyclosporine H or 20 mM verapamil. We have
found no difference in results between cells treated with inhibitors of MDR pump
and cells without incubation with Cyclosporine H or verapamil. Z-stack images
were obtained for accurate analysis. The average intensity of the mitochondrial
staining was measured using the Volocity software (PerkinElmer, Waltham, USA).
The values for WT were set to 100% and the other genotypes were expressed
relative to WT.
Mitochondrial mass was assessed as the percentage of co-localisation of TMRM
fluorescence (mitochondria – red) and fluo-4 am (whole cell – green). Cells were
loaded with 25 nM TMRM and 5 mM fluo-4 am for 40 min at room temperature.
High-resolution z-stack images were obtained. Mitochondrial mass is expressed as
the percentage of co-localization of the green (cytoplasmic) signal and the red
(mitochondrial) signal. This ratio represents the volume of the cell that is occupied
by mitochondria. The co-localization of these signals was set as 100% for WT
cells, to enable comparisons among the genotypes.
Confocal images were obtained using a Zeiss 510 uv-vis CLSM equipped with a
META detection system and a 406 oil immersion objective. TMRM was excited
using the 543 nm laser and fluorescence measured using a 560-nm longpass filter.
Fluo-4 was excited using the 488 nm laser and fluorescence measured above
510 nm. NADH autofluorescence was determined with excitation at 351 nm and
emission at 375–470 nm. FAD autofluorescence was evaluated with excitation at
458 nm and emission at 520 nm. Illumination intensity was kept to a minimum (at
0.1–0.2% of laser output) to avoid phototoxicity and the pinhole set to give an
optical slice of ,2 mm. ATP levels were measured using AT1.03, a ratiometric
construct that undergoes fluorescence resonance energy transfer (FRET) upon
contact with ATP. The data were obtained by quantifying FRET after exciting the
cyan fluorescent protein at 405 nm (measured at 460 to 510 nm), which in turn
excites yellow fluorescent protein, the fluorescence of which is then measured
using a bandpass filter from 515 to 580 nm. All data presented were obtained from
at least 5 coverslips and 2–3 different cell preparations. Measurements of
superoxide using dihydroethidium (DHE) were done as described (Abramov et al.,
2010).
Oxygen consumption
To measure respiration rate in intact cells, approximately 26106 cells were
suspended in HBSS in a Clark-type oxygen electrode thermostatically maintained
at 37 C˚. The oxygen electrode was calibrated with air-saturated water, assuming
406 nmol O atoms/ml at 37 C˚. Oxygen consumption was measured over time with
addition of oligomycin (final concentration 2 mg/ml) and 0.5 mM FCCP.
To measure respiratory control ratio, intact mitochondria were isolated from the
brains of WT and Keap1 KD or Nrf2 KO mice by a method of differential
centrifugation (Domijan and Abramov, 2011) and resuspended in medium
containing 135 mM KCl, 10 mM NaCl, 20 mM HEPES, 0.5 mM KH2PO4,
1 mM MgCl2, 5 mM EGTA at pH 7.1. Oxygen consumption was measured in a
Clark-type oxygen electrode thermostatically maintained at 25 C˚. Glutamate
(5 mM) and malate (5 mM) or 5 mM pyruvate were added to measure Complex I-
linked respiration, succinate (5 mM) with rotenone (5 mM) were added to measure
Complex II-linked respiration. All data were obtained using an Oxygraph Plus
system with Chart recording software.
Mitochondrial complex assays
Activities of respiratory chain complex I, complex II–III (succinate: cytochrome c
reductase), complex IV (cytochrome c oxidase: EC 1.9.3.1) and citrate synthase
(EC 2.3.3.1; CS) were determined as previously described (Hargreaves et al.,
1999). Complex V activity is measured by Blue Native gel electrophoresis (Wittig
et al., 2006). In brief, F1Fo-ATPase (Complex V) activity is measured in a reverse
direction. ATP is hydrolysed into ADP and Pi (inorganic phosphate). The lead ions
in the buffer combine with Pi, which results in the accumulation of lead phosphate,
a grey precipitate where the Complex V band is present. Complex V assay is done
by incubating the gel overnight in 34 mM Tris, 270 mM glycine, 14 mM MgCl2,
6 mM Lead (II) nitrate and 8 mM ATP.
Determination of ROS
MEFs (200,000 per well) were grown in 0.1% gelatin-coated 6-well plates for
24 h. Cells were washed with PBS and loaded with 1 mL of 10 mM 29,79-
dichlorodihydrofluorescein diacetate (Invitrogen Ltd, Paisley, UK) in Hank’s
buffered saline solution (HBSS) for 30 min at 37 C˚, and generation of reactive
oxygen species (ROS) was quantified by the fluorescence intensity of the oxidized
probe using a microtiter plate reader with excitation at 485 nm and emission at
530 nm.
Determination of GSH
Reduced glutathione (GSH) was determined by incubating live cells in Hank’s
buffered saline solution with 40 mM monochlorobimane (mCB) for 1 h (Rice et
al., 1986). The formation of the GS-mCB adduct was quantified using a microtiter
plate reader (SpectraMax M2, Molecular Devices) with excitation at 390 nm and
emission at 490 nm.
Enzyme assays
To determine the enzyme activities in mouse organs, portions (,50 mg) of snap-
frozen tissues were pulverized under liquid nitrogen. The resulting powder was
resuspended in 10 volumes (0.5 ml) of ice-cold 100 mM potassium phosphate
buffer, pH 7.4, containing 100 mM KCl, and complete protease inhibitor cocktail
at a dose of one tablet/10 ml buffer. Following mechanical homogenization in an
ice bath, the homogenate was subjected to centrifugation at 4 C˚ (15,000 g for
10 min). Protein concentrations (Smith et al., 1985) and enzyme activities were
determined in the supernatant fractions. The activity of NAD(P)H:quinone
oxidoreductase 1 (NQO1) was measured in a coupled colorimetric assay using
menadione as a substrate (Prochaska and Santamaria, 1988). Glutathione
transferase (GST) activity was measured spectrophotometrically with 1-chloro-
2–4 dinitrobenzene (CDNB) as a substrate (Habig and Jakoby, 1981). Malic
enzyme activity was determined by monitoring the formation of NADPH using
malate as a substrate (MacDonald and Marshall, 2001).
Statistical analysis
Statistical analysis was performed with Origin 8 (Microcal Software Inc.,
Northampton, MA, USA) software. Student’s t-test was applied. Means
expressed 6 the standard error of the mean (SEM).
Acknowledgements
We thank John Sharkey (University of Dundee) for expert tissue
harvesting, Hiromi Imamura (Japan Science and Technology
Agency) for the AT 1.03 construct, and Stephen Keyse (University
of Dundee) for comments. This work was supported by the
Wellcome Trust/MRC Parkinson’s Consortium Grant and Cancer
Research UK (C20953/A10270). A.Y.A. is a Parkinson’s UK Senior
Research Fellow. A.T.D.-K. is a Research Councils UK Academic
Fellow.
Competing Interests
The authors have no competing interests to declare.
References
Abramov, A. Y. and Duchen, M. R. (2010). Impaired mitochondrial bioenergetics
determines glutamate-induced delayed calcium deregulation in neurons. Biochim.
Biophys. Acta 1800, 297-304.
Abramov, A. Y., Smulders-Srinivasan, T. K., Kirby, D. M., Acin-Perez, R.,
Enriquez, J. A., Lightowlers, R. N., Duchen, M. R. and Turnbull, D. M. (2010).
Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations.
Brain 133, 797-807.
Baird, L. and Dinkova-Kostova, A. T. (2011). The cytoprotective role of the Keap1-
Nrf2 pathway. Arch. Toxicol. 85, 241-272.
Burchell, V. S., Gandhi, S., Deas, E., Wood, N. W., Abramov, A. Y. and Plun-
Favreau, H. (2010). Targeting mitochondrial dysfunction in neurodegenerative
disease: Part I. Expert Opin. Ther. Targets 14, 369-385.
Calkins, M. J., Johnson, D. A., Townsend, J. A., Vargas, M. R., Dowell, J. A.,
Williamson, T. P., Kraft, A. D., Lee, J. M., Li, J. and Johnson, J. A. (2009). The
Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease.
Antioxid. Redox Signal. 11, 497-508.
Chance, B. and Williams, G. R. (1955). Respiratory enzymes in oxidative
phosphorylation. I. Kinetics of oxygen utilization. J. Biol. Chem. 217, 383-393.
Nrf2 and cell bioenergetics 769
B
io
lo
g
y
O
p
e
n
Crunkhorn, S. (2012). Deal watch: Abbott boosts investment in NRF2 activators for
reducing oxidative stress. Nat. Rev. Drug Discov. 11, 96.
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K.,
Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S. et al. (2011). Oncogene-induced
Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-
109.
Domijan, A. M. and Abramov, A. Y. (2011). Fumonisin B1 inhibits mitochondrial
respiration and deregulates calcium homeostasis – implication to mechanism of cell
toxicity. Int. J. Biochem. Cell Biol. 43, 897-904.
Duchen, M. R. (2004). Mitochondria in health and disease: perspectives on a new
mitochondrial biology. Mol. Aspects Med. 25, 365-451.
Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K.,
Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W. et al. (2009). PINK1-
associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced
cell death. Mol. Cell 33, 627-638.
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K.,
Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I. et al.; DEFINE Study
Investigators. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing
multiple sclerosis. N. Engl. J. Med. 367, 1098-1107.
Greco, T., Shafer, J. and Fiskum, G. (2011). Sulforaphane inhibits mitochondrial
permeability transition and oxidative stress. Free Radic. Biol. Med. 51, 2164-2171.
Habig, W. H. and Jakoby, W. B. (1981). Glutathione S-transferases (rat and human).
Methods Enzymol. 77, 218-231.
Hargreaves, I. P., Heales, S. J. and Land, J. M. (1999). Mitochondrial respiratory
chain defects are not accompanied by an increase in the activities of lactate
dehydrogenase or manganese superoxide dismutase in paediatric skeletal muscle
biopsies. J. Inherit. Metab. Dis. 22, 925-931.
Hayes, J. D., McMahon, M., Chowdhry, S. and Dinkova-Kostova, A. T. (2010).
Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway.
Antioxid. Redox Signal. 13, 1713-1748.
Imamura, H., Nhat, K. P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y., Nagai,
T. and Noji, H. (2009). Visualization of ATP levels inside single living cells with
fluorescence resonance energy transfer-based genetically encoded indicators. Proc.
Natl. Acad. Sci. USA 106, 15651-15656.
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T.,
Hayashi, N., Satoh, K., Hatayama, I. et al. (1997). An Nrf2/small Maf heterodimer
mediates the induction of phase II detoxifying enzyme genes through antioxidant
response elements. Biochem. Biophys. Res. Commun. 236, 313-322.
Kensler, T. W., Wakabayashi, N. and Biswal, S. (2007). Cell survival responses to
environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol.
Toxicol. 47, 89-116.
Kensler, T. W., Egner, P. A., Agyeman, A. S., Visvanathan, K., Groopman, J. D.,
Chen, J. G., Chen, T. Y., Fahey, J. W. and Talalay, P. (2013). Keap1-nrf2
signaling: a target for cancer prevention by sulforaphane. Top. Curr. Chem. 329, 163-
177.
Kim, T. H., Hur, E. G., Kang, S. J., Kim, J. A., Thapa, D., Lee, Y. M., Ku, S. K.,
Jung, Y. and Kwak, M. K. (2011). NRF2 blockade suppresses colon tumor
angiogenesis by inhibiting hypoxia-induced activation of HIF-1a. Cancer Res. 71,
2260-2275.
Kirby, J., Halligan, E., Baptista, M. J., Allen, S., Heath, P. R., Holden, H., Barber,
S. C., Loynes, C. A., Wood-Allum, C. A., Lunec, J. et al. (2005). Mutant SOD1
alters the motor neuronal transcriptome: implications for familial ALS. Brain 128,
1686-1706.
Lee, J. M., Calkins, M. J., Chan, K., Kan, Y. W. and Johnson, J. A. (2003a).
Identification of the NF-E2-related factor-2-dependent genes conferring protection
against oxidative stress in primary cortical astrocytes using oligonucleotide
microarray analysis. J. Biol. Chem. 278, 12029-12038.
Lee, J. M., Shih, A. Y., Murphy, T. H. and Johnson, J. A. (2003b). NF-E2-related
factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and
increased concentrations of intracellular calcium in primary cortical neurons. J. Biol.
Chem. 278, 37948-37956.
Liby, K. T. and Sporn, M. B. (2012). Synthetic oleanane triterpenoids: multifunctional
drugs with a broad range of applications for prevention and treatment of chronic
disease. Pharmacol. Rev. 64, 972-1003.
MacDonald, M. J. and Marshall, L. K. (2001). Survey of normal appearing mouse
strain which lacks malic enzyme and Nad+-linked glycerol phosphate dehydrogenase:
normal pancreatic beta cell function, but abnormal metabolite pattern in skeletal
muscle. Mol. Cell. Biochem. 220, 117-125.
Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel,
C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W. et al. (2010).
Global mapping of binding sites for Nrf2 identifies novel targets in cell survival
response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38,
5718-5734.
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H.,
Yamamoto, M. and Motohashi, H. (2012). Nrf2 redirects glucose and glutamine
into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66-79.
Nguyen, T., Nioi, P. and Pickett, C. B. (2009). The Nrf2-antioxidant response element
signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291-
13295.
Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A., Ruiz, S., Meyer, C. J. and
Warnock, D. G. (2011a). Effect of bardoxolone methyl on kidney function in patients
with T2D and Stage 3b-4 CKD. Am. J. Nephrol. 33, 469-476.
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B.,
Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H. et al.; BEAM Study
Investigators. (2011b). Bardoxolone methyl and kidney function in CKD with type 2
diabetes. N. Engl. J. Med. 365, 327-336.
Prochaska, H. J. and Santamaria, A. B. (1988). Direct measurement of
NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening
assay for anticarcinogenic enzyme inducers. Anal. Biochem. 169, 328-336.
Rice, G. C., Bump, E. A., Shrieve, D. C., Lee, W. and Kovacs, M. (1986).
Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlor-
obimane: some applications to radiation and drug resistance in vitro and in vivo.
Cancer Res. 46, 6105-6110.
Schuit, F. C., Huypens, P., Heimberg, H. and Pipeleers, D. G. (2001). Glucose
sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells
in gut, pancreas, and hypothalamus. Diabetes 50, 1-11.
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H.,
Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. and Klenk, D. C.
(1985). Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
Taguchi, K., Maher, J. M., Suzuki, T., Kawatani, Y., Motohashi, H. and Yamamoto,
M. (2010). Genetic analysis of cytoprotective functions supported by graded
expression of Keap1. Mol. Cell. Biol. 30, 3016-3026.
Talalay, P. (2000). Chemoprotection against cancer by induction of phase 2 enzymes.
Biofactors 12, 5-11.
Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T. W., Yamamoto, M. and
Biswal, S. (2002). Identification of Nrf2-regulated genes induced by the chemopre-
ventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62, 5196-
5203.
Vaarmann, A., Gandhi, S., Gourine, A. V. and Abramov, A. Y. (2010). Novel
pathway for an old neurotransmitter: dopamine-induced neuronal calcium signalling
via receptor-independent mechanisms. Cell Calcium 48, 176-182.
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi,
S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R. et al. (2003). Keap1-null
mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet.
35, 238-245.
Wang, G. J., Randall, R. D. and Thayer, S. A. (1994). Glutamate-induced intracellular
acidification of cultured hippocampal neurons demonstrates altered energy metabo-
lism resulting from Ca2+ loads. J. Neurophysiol. 72, 2563-2569.
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314.
Wittig, I., Braun, H. P. and Scha¨gger, H. (2006). Blue native PAGE. Nat. Protoc. 1,
418-428.
Wu, K. C., Cui, J. Y. and Klaassen, C. D. (2011). Beneficial role of Nrf2 in regulating
NADPH generation and consumption. Toxicol. Sci. 123, 590-600.
Yao, Z., Gandhi, S., Burchell, V. S., Plun-Favreau, H., Wood, N. W. and Abramov,
A. Y. (2011). Cell metabolism affects selective vulnerability in PINK1-associated
Parkinson’s disease. J. Cell Sci. 124, 4194-4202.
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D. and
Zhang, D. D. (2011). Therapeutic potential of Nrf2 activators in streptozotocin-
induced diabetic nephropathy. Diabetes 60, 3055-3066.
Nrf2 and cell bioenergetics 770
B
io
lo
g
y
O
p
e
n
